

Unlock the world's most dynamic precision medicine network

Clinico-genomics for GLP-1 drug discovery and development

Accelerate obesity and metabolic diseases research and therapeutic development with the largest continuously growing Glucagon-like-Peptide-1 (GLP-1) receptor agonist clinico-genomic registry with full patient consent for recontact.

Comprehensive Whole Exome Sequencing Platform

The first and only FDA de novo class II authorized exome platform (Exome+[®]) optimized to be the most comprehensive and technically sensitive WES offering available.

Longitudinal Clinical Insights

De-identified, OMOP-standardized EHR integrations, including full clinical data & lab results, across North America. Regular data refreshes enable life sciences to follow the patient journey beyond an initial encounter.

Diverse Claims Data

Insights into medication usage, treatment adherence and cost of care through access to medical, pharmacy and mortality data from a partnership with Komodo Health.

Proprietary Clinico-Genomic Registry & Support



Exome+[®] sequencing data linked with rich longitudinal clinical data from health system partners across NA



Multi-site network protocol aggregating cohorts for a range of therapeutic areas



Geographically and genetically diverse population consented for Life Sciences recontact



World class analytical capabilities and a dedicated in-house Translational Research team

Let the power of Exome+[®] drive your drug discovery and development

Target Identification and Validation

New Biomarker Discovery


Evidence and Outcomes Research

Through health system partnerships across North America, Helix has built a rapidly growing clinico-genomic cohort of ~28,000 GLP-1 receptor agonist treated patients


Therapeutic agents assessed (short and long acting):

Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide, Semaglutide, Beinsaglutide, Tirzepatide


GLP-1 Cohort: Diabetes vs. Non



% of patients with X number of measurements



% Total Cohort vs. BMI Reading



Type 2 Diabetes:

Identify and analyze *GLP1R* variants associated with Type 2 diabetes



GLP-1 custom cohort:

Created based upon a range of inclusion and exclusion criteria



Obesity:

Analyze the emerging impact of GLP-1 receptor agonists in obesity



Key metabolic and genetic factors associated with weight loss in semaglutide. Levy et.al. demonstrates the robust utility of genomic data to analyze variants related to therapeutic response.

1

Curating a clinico-genomic cohort of metabolic patients treated with semaglutide

2

Building a predictive model to accurately determine 12-month weight loss with treatment and highlight the importance of advancing precision medicine for obesity management

~28,000 linked records enable expansion of similar studies to drive development with:



Research ready datasets:
Easy to access and ready to drive impact for your needs



Custom delivered insights:
Flexible solution enabling you to work with us on quick analysis or end-to-end research projects for T2D, obesity and more.